Phase II of the combination of Olutasidenib and Azacitidine was based on a study involving four cohorts of patients: treatment-naïve patients with AML; R/R AML and MDS patients with no prior exposure to HMA or IDH1 inhibitors; patients R/R to HMA; and patients with prior exposure to IDH1 inhibitors [43]. This evidence concerns the gene IDH1 and myelodysplastic syndrome.